Dishman Carbogen Amcis Reports Decline in Financial Performance, Receives 'Strong Sell' Rating

Dishman Carbogen Amcis, a smallcap pharmaceutical company, recently announced its financial results for the quarter ending June 2024. The company's stock has been given a 'Strong Sell' rating by MarketsMOJO.

According to the financials, Dishman Carbogen has seen a significant decline in its performance, with a score of -20 compared to -9 in the previous quarter. However, there are some positive aspects to the company's financials.

One of the strengths of Dishman Carbogen is its Debtors Turnover Ratio, which has been the highest in the last five half yearly periods at 5.67 times. This indicates that the company has been able to settle its debtors at a faster rate.

On the other hand, there are some areas of concern for the company. The net sales for the quarter have fallen by -27.59% year on year, indicating a negative trend in the near term. The Profit Before Tax less Other Income (PBT) has also seen a significant decline of -420.34% year on year, and the Profit After Tax (PAT) has fallen by -524.3% year on year. The company's ability to manage interest payments has also deteriorated, with the Operating Profit to Interest ratio being the lowest in the last five quarters.

Moreover, the Debt-Equity Ratio has been the highest in the last five half yearly periods, indicating that the company is borrowing more to fund its operations. This could potentially lead to a stressed liquidity situation.

In conclusion, Dishman Carbogen Amcis has seen a negative trend in its financial performance for the quarter ending June 2024. The company's stock has been given a 'Strong Sell' rating, and investors should carefully consider these financials before making any investment decisions.